Metreton

Pemphigus, Ophthalmia, Sympathetic, Chorioretinitis + 95 more
Treatment
55 FDA approvals
20 Active Studies for Metreton

What is Metreton

PrednisoneThe Generic name of this drug
Treatment SummaryDiphenhydramine is an antihistamine medication used to treat allergies, hay fever, and asthma. It is commonly used to reduce the symptoms of itching, sneezing, and runny nose. It is less likely to cause drowsiness than other similar medications and is often used in veterinary medicine.
PredniSONEis the brand name
image of different drug pills on a surface
Metreton Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
PredniSONE
Prednisone
1972
681

Approved as Treatment by the FDA

Prednisone, commonly known as PredniSONE, is approved by the FDA for 55 uses which include Anemia, Hemolytic and Uremia .
Anemia, Hemolytic
Uremia
Thrombocytopenia
Conjunctivitis
Helps manage Ocular Inflammation
Mycosis Fungoides (MF)
Helps manage Mycosis Fungoides (MF)
Secondary thrombocytopenia
Diuresis
Allergic Rhinitis (AR)
Helps manage Allergic Rhinitis (AR)
non-suppurative Thyroiditis
Primary adrenocortical insufficiency
Adrenal Cortex Hormones
Helps manage unresponsive to topical corticosteroids
acquired immune hemolytic anemia
Crohn Disease
Helps manage acute Crohn's Disease (CD)
Atopic Dermatitis
Helps manage Atopic Dermatitis
Congenital Hypoplastic Anemia
Congenital Adrenal Hyperplasia (CAH)
Neurologic Involvement
Immune Thrombocytopenia (ITP)
Disseminated tuberculosis
Used to treat Disseminated tuberculosis in combination with Aminosalicylic acid
Drug hypersensitivity reaction
Contact Dermatitis
Mycosis Fungoides
Helps manage Mycosis Fungoides (MF)
Thyroiditis
Ulcerative Colitis
Helps manage Ulcerative Colitis
Sarcoidosis
Helps manage symptomatic Sarcoidosis
Secondary adrenocortical insufficiency
Malignant Neoplasms
Stevens-Johnson Syndrome
induction of Diuresis
Idiopathic Nephrotic Syndrome
symptomatic Sarcoidosis
Helps manage symptomatic Sarcoidosis
Asthma
Helps manage Asthma
Ulcerative Colitis
Helps manage Ulcerative Colitis
Ocular Inflammation
Helps manage Ocular Inflammation
Pemphigus
Helps manage Pemphigus
Trichinosis
Pemphigus
Helps manage Pemphigus
Systemic Lupus Erythematosus (SLE)
Adrenal Insufficiency
Addison Disease
Lupus Erythematosus
Proteinuria
Uremia
Bullous dermatitis herpetiformis
Helps manage Bullous dermatitis herpetiformis
Tuberculosis
Used to treat fulminating Tuberculosis in combination with Aminosalicylic acid
Serum Sickness
exfoliative erythroderma
Helps manage exfoliative erythroderma
Anemia, Diamond-Blackfan
Lupus
Congenital adrenal hyperplasia
Patient Participation
Tuberculosis
Used to treat Disseminated tuberculosis in combination with Aminosalicylic acid
Aspiration Pneumonitis
Drug Allergy
Asthma
Helps manage Asthma

Effectiveness

How Metreton Affects PatientsAllergies happen when an allergen (like pollen) interacts with and activates the antibodies on mast cells and basophils. This causes these cells to release histamine and other chemical mediators, which can cause itching, flushing, headaches, a racing heart rate, and other symptoms. Chlorpheniramine is a drug that works by blocking the histamine receptors in the body, which helps to reduce the symptoms of allergies like sneezing, runny nose, itchy eyes, and watery eyes.
How Metreton works in the bodyChlorpheniramine blocks the effects of histamine, which reduces the symptoms of allergies. It does this by attaching to the histamine H1 receptor and preventing it from responding to histamine.

When to interrupt dosage

The suggested measure of Metreton depends upon the determined condition, including upper respiratory indications, Coughing and Inflammation. The amount of dosage is contingent upon the administration technique (e.g. Kit; Syrup - Oral or Liquid - Oral) featured in the table beneath.
Condition
Dosage
Administration
Dermatomyositis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
prophylaxis of graves ophthalmopathy
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Craniotomy
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
exfoliative erythroderma
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Addison Disease
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
varicella-zoster virus acute retinal necrosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Psoriasis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Trichinosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
induction of Diuresis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Diuresis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Sarcoidosis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Brain
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Brain
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Optic Neuritis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Congenital adrenal hyperplasia
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Malignant Neoplasms
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
HIV Positive
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Red-Cell Aplasia, Pure
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Psoriatic Arthritis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit
Ulcerative Colitis
, 5.0 mg/mL, 2.5 mg, 10.0 mg, 5.0 mg, 20.0 mg, 1.0 mg, 50.0 mg, 0.2 mg, 0.1 mg, 2.0 mg/mg, 2.0 mg, 5.0 mg/mg
, Oral, Solution, Solution - Oral, Tablet - Oral, Tablet, Solution, concentrate - Oral, Solution, concentrate, Tablet, delayed release - Oral, Tablet, delayed release, Kit

Warnings

Metreton Contraindications
Condition
Risk Level
Notes
Mycoses
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Prednisone may interact with Pulse Frequency
There are 20 known major drug interactions with Metreton.
Common Metreton Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Abatacept.
Abetimus
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Prednisone is combined with Acteoside.
Metreton Toxicity & Overdose RiskThe lowest toxic dose of the drug for rats, mice, and guinea pigs has been found to be 306mg/kg, 130mg/kg, and 198mg/kg, respectively. It can also cause mild reproductive harm to women of childbearing age.
image of a doctor in a lab doing drug, clinical research

Metreton Novel Uses: Which Conditions Have a Clinical Trial Featuring Metreton?

163 active trials are currently underway to evaluate the potential of Metreton to reduce Allergy symptoms from vaccines, Eye issues, and Coughing.
Condition
Clinical Trials
Trial Phases
Drug Allergy
2 Actively Recruiting
Phase 3, Phase 2
Asthma
92 Actively Recruiting
Phase 1, Phase 4, Early Phase 1, Phase 2, Not Applicable, Phase 3
Tuberculosis
0 Actively Recruiting
Relapsing Polychondritis
1 Actively Recruiting
Phase 2
Giant Cell Arteritis
3 Actively Recruiting
Phase 3, Phase 1, Phase 2
Lupus
65 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
Tennis Elbow
0 Actively Recruiting
Acute Coryza
0 Actively Recruiting
Ulcerative Colitis
14 Actively Recruiting
Phase 3, Phase 2, Not Applicable, Phase 4, Phase 1
Bell Palsy
0 Actively Recruiting
Polymyalgia Rheumatica
3 Actively Recruiting
Phase 3, Phase 2
Patient Participation
0 Actively Recruiting
Crohn Disease
0 Actively Recruiting
Chorioretinitis
0 Actively Recruiting
Acne Vulgaris
2 Actively Recruiting
Phase 1, Phase 2, Early Phase 1
Brain
7 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1
acute Bursitis
0 Actively Recruiting
Brain
0 Actively Recruiting
Arthritis, Juvenile
1 Actively Recruiting
Not Applicable
Bullous dermatitis herpetiformis
0 Actively Recruiting

Metreton Reviews: What are patients saying about Metreton?

5Patient Review
11/4/2022
Metreton for Depression
This medication has been a lifesaver for me. I've been taking it for anxiety and depression for about a year now, and it really makes a difference. It calms my mind and allows me to get a good night's sleep, which is something that was previously impossible for me. If you're struggling with anxiety, I would highly recommend giving this treatment a try.
5Patient Review
10/11/2022
Metreton for Depression
I'm 82 years old and have battled depression my entire life. This medication has made me feel incredible, and I would recommend it to anyone. Thank you, Mirtazapine!
5Patient Review
11/4/2022
Metreton for Depression
I've been taking 7.5mg of this medication for about a year to help with anxiety and mild depression. It definitely takes the edge off and helps me sleep at night, which is amazing. I would recommend it to anyone struggling with similar issues.
5Patient Review
10/11/2022
Metreton for Depression
I am an 82 year old woman who has struggled with depression for my entire life. This medication has made me feel better than ever before and I would recommend it to anyone. Thank you Mirtazapine!
5Patient Review
11/4/2022
Metreton for Depression
This dosage of medication has really helped me to cope with my anxiety and depression. It doesn't make me drowsy, but rather allows me to wake feeling refreshed after a good night's sleep. I recommend giving it a try if anxiety is keeping you up at night.
5Patient Review
10/11/2022
Metreton for Depression
As an 82 year old woman who has dealt with depression my entire life, this treatment was a godsend. I would recommend it to anyone else in a similar situation.
4.7Patient Review
9/26/2022
Metreton for Depression
I've been using mirtazapine for a while now and it's helped me a lot with depression, anxiety, and insomnia. Recently though, I think it might be causing me to have nightmares every night. Not sure if it's just losing some effectiveness after long-term use or what, but I'm going to keep an eye on it and maybe switch to something else if things get worse.
4.7Patient Review
9/26/2022
Metreton for Depression
I've been taking mirtazapine for four years now, and it's done a great job treating my depression, anxiety, and insomnia. Recently, though, I think it's been giving me nightmares every night. Not sure if it's just because I've been on the medication for awhile or what, but if this keeps up I might have to switch to something else.
4.7Patient Review
9/26/2022
Metreton for Depression
I've been taking mirtazapine for four years now and it's done wonders for my depression, anxiety, and insomnia. Recently, however, I think it's started giving me nightmares every night. Not sure why that is, but it's becoming a bit of a problem. Might try something else if things don't improve soon.
4.3Patient Review
10/20/2022
Metreton for Major Depressive Disorder
It made me really hungry at first, but that side effect dissipated after about a month. It's helped me sleep and takes the edge off my symptoms. Overall, I'm happy with it!
4.3Patient Review
10/20/2022
Metreton for Major Depressive Disorder
It made me really hungry at first, but that went away after a month. This medication helps me sleep and takes the edge off my symptoms. I'm generally happy with it!
4.3Patient Review
10/20/2022
Metreton for Major Depressive Disorder
I was really hungry when I first started taking this medication, but that side effect subsided after a month or so. It's helped me sleep and makes my symptoms more manageable. All in all, I'm pretty happy with it!
4Patient Review
10/4/2022
Metreton for Major Depressive Disorder
Mirtazapine was prescribed to me for my depression. I found that it really helped with my anxiety and insomnia, but after a month it didn't do anything for my depression. It's a powerful pill, but it just wasn't the right one for me.
4Patient Review
8/18/2022
Metreton for Depression
This medication has been really helpful to me. I only use 7.5 mg, which is half the recommended dosage, but it does the trick!
4Patient Review
10/4/2022
Metreton for Major Depressive Disorder
Mirtazapine was prescribed to me for my depression. I had no other side effects than the common sedative affect, which is good. It completely took away all my anxiety and insomnia, but after over a month it did nothing for my depression.
4Patient Review
10/4/2022
Metreton for Major Depressive Disorder
Mirtazapine was prescribed to me for my depression. I experienced the common sedative effect, but it was otherwise unnoticeable. It helped with my anxiety and insomnia, but after a month it had no effect on my depression.
4Patient Review
8/18/2022
Metreton for Depression
This has been a great help to me. I only use 7.5 mg, half of what my doctor prescribed, and it works perfectly.
4Patient Review
8/18/2022
Metreton for Depression
I only use half the recommended dosage, but it still does wonders for me. Really happy with this medication.
1.7Patient Review
9/13/2022
Metreton for Depression
I was prescribed this for depression, anxiety and insomnia. Unfortunately, after taking just one pill I felt incredibly drugged the next morning. I still don't feel normal days later. Needless to say, I won't be taking this again.
1.7Patient Review
9/13/2022
Metreton for Depression
I was prescribed this for depression, anxiety and insomnia. I took one pill before bed, but instead of feeling sleepy, I felt completely drugged and awake. This continued all night, and the next day I felt nauseous and dizzy. I couldn't function at all. Two days later and I still don't feel normal. Needless to say, I won't be taking this again!
1.7Patient Review
9/13/2022
Metreton for Depression
I was prescribed this for depression, anxiety, and insomnia. However, after taking just one pill of 15mg around 11:45 pm, I found myself still awake at 4 am. I felt jittery and drugged; it was awful. In addition, the following day I felt completely exhausted, dizzy, and nauseous—I couldn't function at all. Two days later and I still don't feel normal. Needless to say, I won't be taking this again.
1Patient Review
8/13/2022
Metreton for Major Depressive Disorder
Out of the six other medications I've tried, this one was by far the worst. It made everything more overwhelming and increased my suicidal thoughts and intentions. Unless you have tried other medications beforehand, take this with extreme caution if at all. I would not recommend it whatsoever.
1Patient Review
8/13/2022
Metreton for Major Depressive Disorder
This medication made everything worse and actually increased my suicidal thoughts. I would not recommend it to anyone.
1Patient Review
8/13/2022
Metreton for Major Depressive Disorder
I've tried other medications before and this one is by far the worst. It made everything more overwhelming and increased my suicidal thoughts. I wouldn't recommend it to anyone.

Patient Q&A Section about metreton

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Clinical Trials for Metreton

Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Have you considered Metreton clinical trials? We made a collection of clinical trials featuring Metreton, we think they might fit your search criteria.Go to Trials
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Metreton clinical trials? We made a collection of clinical trials featuring Metreton, we think they might fit your search criteria.Go to Trials
Image of BAMF Health in Grand Rapids, United States.

AB001 for Prostate Cancer

18+
Male
Grand Rapids, MI
This study is designed to investigate the safety, tolerability, and effectiveness of a new treatment called AB001 in both 177Lu-PSMA naïve and 177Lu-PSMA experienced patients with advanced prostate cancer. AB001 targets a specific protein found on prostate cancer cells called prostate specific membrane antigen (PSMA) and delivers radioactive particles to kill the cancer cells. The primary goal of the study is to determine the safety profile of AB001 and how well patients tolerate the treatment. Researchers also aim to identify the best dose and schedule for further testing and clinical development. AB001 could be a promising treatment because it uses alpha particles, which are highly effective at damaging cancer cells while causing minimal harm to surrounding healthy tissue. This targeted approach is expected to result in fewer side effects compared to other types of radiation therapy. This Phase 1 study consists of two main parts: dose escalation and dose expansion. In the first part, researchers will test different doses of AB001 to find the safest and most effective dose. In the second part, the selected dose will be further evaluated to refine the treatment schedule and gather more data on its effectiveness and safety. The study aims to provide early data on the anti-tumour activity of AB001 and determine the best dose and treatment schedule for future trials. Researchers hope that AB001 will offer a new and effective treatment option for patients with advanced prostate cancer.
Phase 1
Recruiting
BAMF Health (+3 Sites)Margaret YuARTBIO Inc.
Have you considered Metreton clinical trials? We made a collection of clinical trials featuring Metreton, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security